

Press release for immediate release

## Genomtec appoints new Chief Technology Officer

**Wrocław, Poland - July 11, 2022. - Genomtec S.A. "GMT", a NewConnect-listed MedTech company specializing in the development of advanced technology in the area of point-of-care (POCT) genetic diagnostics, has appointed Richard Moore as the new Chief Technology Officer to drive its next generation of products and systems. Richard replaces Jason Reece who announced his intentions to retire.**

Richard Moore joins from GeneDrive where he most recently served as the Head of Engineering and comes with over 25 years of experience in new product introduction and design for manufacturability within the medical devices and electronics industry. During his career in UK and Canada Richard demonstrated success in leading electronics, mechanical and software engineering teams to develop new products that meet customer requirements, quality, regulatory and manufacturability requirements. Richard gained broad range of knowledge of Good Manufacturing Practices and a clear understanding of design for manufacturability during his work at: GeneDrive Diagnostics Limited in Manchester, UK; Optos Plc, Dunfermline, UK; DySIS Medical Ltd., Edinburgh, UK; Cadence Design Systems, Livingston, UK; Newbridge Networks Corporation, Ontario, Canada and GEC Plessey Semiconductors, Plymouth, UK.

*- I am very excited to welcome Richard Moore as our new Chief Technology Officer. His experience in moving the production process from design to scalable manufacturing is proven and it is exactly what we need today. I also would like to thank Jason Reece for his engagement and support during last critical years for Genomtec, which brought us to the phase of a registered platform. Without his passion and knowledge, it would be difficult to accomplish our technical milestones. – said Miron Tokarski, Chief Executive Officer in Genomtec.*

*- I am thrilled to join the international team of experts from Genomtec and contribute to further dynamic growth of the company. I have gained qualities and skills, which are the right fit to the company's current needs. We will for sure work on every market feedback on Genomtec®ID we would receive to make the platform even better than it is now. SNAAT® technology is ground-breaking and its use needs excellent engineering processes which I hope to lead the team to and strengthen the company products and solutions even further. – said Richard Moore, Chief Technology Officer in Genomtec.*

On June 8, 2022, Genomtec announced obtaining the CE-IVD mark for its flagship solution, the Genomtec®ID Respiratory Panel 5-Plex (RP5-PLEX). It is the only diagnostic panel of its kind to simultaneously test for the presence of up to 5 viruses and bacteria in the same test available in Europe. The Genomtec®ID RP5-PLEX panel detects Influenza A and B viruses, RSV (Respiratory Syncytial Virus), SARS-CoV-2 and the atypical bacteria *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae*.

#####

## **Additional information at:**

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

## **About Genomtec:**

Genomtec is an innovative medical technology company engaged in the development and commercialization of a mobile platform used in molecular clinical diagnostics of, among others, a number of infectious diseases, including rapid diagnostic tests applicable, among others, in the detection of COVID-19 disease caused by SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile genetic diagnostic system. The analyzer is a unique solution in the world in this type of equipment. It will allow for fast and precise molecular analysis outside the laboratory environment and without the need to involve qualified laboratory staff. The system utilizes microfluidic technology and proprietary, patented SNAAT® isothermal technology. Proper design of the system enables the process to be performed in a short 35-45 minutes, with efficiencies equal to, and in some cases exceeding, the quality of laboratory PCR assays.

On June 8, 2022, Genomtec announced obtaining CE-IVD certification for the Genomtec®ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of influenza A and B viruses, Respiratory Syncytial Virus (RSV), SARS-CoV-2, and the atypical bacteria *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae*. The Genomtec®ID analyzer, into which a reaction card (panel) is inserted along with a patient sample for genetic testing, is one of the smallest portable genetic laboratories in the world.

The development and production process is carried out in close cooperation with international CMO (Contract Manufacturing Organization) companies. The commercialization of the flagship solution took place in the first half of 2022.

Genomtec was founded in 2016. The headquarters of Genomtec SA is located in Wrocław, Poland.

For more information: [www.genomtec.com](http://www.genomtec.com)